Background: The identification of non-tuberculosis (TB) mycobacterial (NTM) infection remains a significant challenge. This study aims to investigate the diagnostic value of multicolour nested ...

The overall failed test rate was 10.6% (range 5.9% in Moldova and Pakistan to 16.3% in the DRC). When data was pulled directly from the GeneXpert machine as opposed to the laboratory registers, a ...

Please provide your email address to receive an email when new articles are posted on . The development of the Xpert MTB/RIF assay has been the most important breakthrough for the diagnosis of ...

FDA Expands Xpert MTB/RIF Test Use The Food and Drug Administration (FDA) has granted clearance for the Cepheid Xpert MTB/RIF Assay to help determine if patients with suspected tuberculosis (TB) can ...

Please provide your email address to receive an email when new articles are posted on . An updated version of the Xpert MTB/RIF assay, which includes new gene target ...

In the policy statement on the Xpert MTB/RIF test in 2011, the WHO recommended the use of the test as an initial diagnostic tool among children with suspected HIV associated TB or MDR TB based on ...

Tuberculous meningitis (TBM) is a serious and often fatal illness that is difficult to diagnose particularly in resource-poor areas and is especially common in individuals infected with HIV. In this ...

Cepheid Inc., produces Xpert MTB/RIF, which is an automated, fast test for TB using molecular diagnostics. Compared to the standard test for TB in developing countries, sputum smear microscopy, it is ...